IP Library Granted Patent US 11,207,430
Granted Patent B2
US 11,207,430 · App. 15/369,661 · Granted Dec 28, 2021

Gadolinium expressed lipid nanoparticles for magnetic resonance imaging

Inventors: Rodney J. Y. Ho (Mercer Island, WA); John D. Hoekman (Seattle, WA); Ken Maravilla (Bellevue, WA)
Assignee: University of Washington
A61K49/1824A61K49/085A61K49/1806A61K49/1812A61K49/1881A61K51/0408A61K51/0497A61K51/1227B82Y5/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,207,430
App. No.
15/369,661
Granted
Dec 28, 2021
Kind
B2
Abstract

Lipid nanoparticles expressing metal ions and methods for using the compositions for magnetic resonance imaging.

Claims (12)

1. A nanoparticle, comprising:

(a) a phospholipid selected from distearoyl-phosphocholine (DSPC) or dipalmitoyl sphingomyelin (DPSP);

(b) |N-(carbonyl-methoxypolyethyleneglycol)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (mPEG-DSPE); and

(c) 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-diethylenetriaminepenta-acetyl (DSPE-DTPA) with a chelated Gd 3+ ion, wherein the nanoparticle is not a liposome, and wherein the nanoparticle has a T1 relaxivity constant (r 1 ) of at least about 133 sec −1 mM −1 as determined by a magnetic resonance (MR) scanner;

wherein the mPEG-DSPE is present in the amount from about 5 to about 20 mole percent of the combined phospholipid, the mPEG-DSPE, and DSPE-DTPA, and

wherein the phospholipid:mPEG-DSPE:DSPE-DTPA ratio is from 8:1:0.9 to 8:2:1.

2. The nanoparticle of claim 1 , wherein the N-(carbony]l-methoxypolyethyleneglycol)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (mPEG-DSPE) is N-(carbonyl-methoxypolyethyleneglycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (mPEG-2000-DSPE).

3. The nanoparticle of claim 1 , further comprising a targeting moiety.

4. The nanoparticle of claim 3 , wherein the targeting moiety is selected from the group consisting of a protein, a polypeptide, a peptide, an antibody or fragment thereof, a small molecule, a sugar or polysaccharide or derivative thereof, and a nucleic acid.

5. A composition, comprising a carrier and a plurality of the nanoparticles of claim 1 .

6. The nanoparticle of claim 1 , wherein the nanoparticle comprises 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and N-(carbonyl-methoxypolyethyleneglycol-2000)-1,2-distearoyl-sn-glycero-3 phosphoethanolamine (mPEG-2000-DSPE).

7. The nanoparticle of claim 1 , wherein the nanoparticle does not have a solid core structure.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 14, 2022
From: UNIVERSITY OF WASHINGTON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 062122/0700 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2017
From: HO, RODNEY J.Y.; HOEKMAN, JOHN D.; MARAVILLA, KEN
To: UNIVERSITY OF WASHINGTON
Reel/Frame 041867/0207 →
Continuity (5)
Continuation 13208100 · Aug 11, 2011
Continuation PCTUS2010024324 · Feb 16, 2010
Provisional Application 61152459 · Feb 13, 2009
Provisional Application 61162989 · Mar 24, 2009
Related Publication 20170173190A1 · Jun 22, 2017